Samsung Bio, Expands Communication with 'Minor Shareholders' through Spin-off

[Financial News] Samsung Biologics has created an opportunity to communicate directly with minor shareholders regarding the promotion of the spin-off, aiming to provide transparent and prompt management information.
Samsung Biologics held an online meeting for minor shareholders on the afternoon of the 29th, focusing on the spin-off plan. About 70 minor shareholders attended this meeting, which was conducted using the Zoom platform, and discussions continued for about an hour regarding the background, schedule, and investor protection measures of the spin-off.
Key executives, including Yoo Seung-ho, Head of Management Support Center (Vice President) at Samsung Biologics, and Kim Hyung-jun, Head of Management Support Office (Vice President) at Samsung Bioepis, participated as presenters.
They explained in detail the background of restructuring the business structure into a spin-off method to strengthen the independence and expertise between the Contract Development and Manufacturing Organization (CDMO) business and the biosimilar business.
Through this spin-off, Samsung Biologics aims to allow independent market evaluations for the two different business areas and enable investors to establish strategies that match their investment preferences.
Vice President Yoo stated, "From an investor's perspective, as the business structure becomes less complex and options expand, more clear and efficient investment decisions will be possible."
During the meeting, questions from minor shareholders about the method of stock allocation and future stock price trends were also addressed.
After the spin-off, existing Samsung Biologics shareholders will receive shares of Samsung Biologics and the newly established Samsung Epis Holdings at a ratio of 0.6503913 to 0.3496087 compared to their existing shares. Fractional shares other than whole numbers will be treated as odd lots and refunded in cash.
Samsung Biologics reiterated its commitment to providing shareholders with prompt and sufficient explanations through this meeting.
Even immediately after the spin-off announcement, a meeting was promptly held for journalists and analysts. Positive evaluations are emerging from the securities industry, and there are prospects that this spin-off could be a positive momentum for the growth strategies of Samsung Biologics and its subsidiaries.
Vice President Yoo stated, "This meeting was organized to communicate directly with our shareholders," and added, "We will continue to strengthen communication through various channels in the future."
This spin-off is being pursued with the target spin-off date of October 1st, and Samsung Biologics is set to become a pure CDMO business operator, while Samsung Epis Holdings will focus on new growth engines as an investment holding company.


vrdw88@fnnews.com Kang Jung-mo Reporter